SYRE

Spyre Therapeutics initiated with a Hold at JonesResearch

JonesResearch initiated coverage of Spyre Therapeutics (SYRE) with a Hold rating and no price target Spyre is a clinical-stage biotech developing half-life extended antibodies for the treatment of inflammatory bowel disease, the analyst tells investors in a research note. The firm sees a balanced risk/reward profile into near-term data catalysts. Spyre ‘s lead monotherapies could drive blockbuster sales, but the opportunities appear priced into the stock, contends JonesResearch.

Pick the best stocks and maximize your portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on SYRE:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.